Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €453.42 EUR
Change Today 0.00 / 0.00%
Volume 0.0
RHPP On Other Exchanges
Symbol
Exchange
EN Paris
EN Paris
New York
OTC US
BrsaItaliana
Mexico
Frankfurt
Frankfurt
NASDAQ GM
As of 10:30 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

54, Rue La Boétie

Paris, 75008

France

Phone: 33 1 53 77 40 00

Fax: 33 1 53 77 42 96

n the United States and Japan. Apidra: Apidra (insulin glulisine) is a rapid acting analog of human insulin. Apidra is indicated for the treatment of adults with type 1 or type 2 diabetes for supplementary glycemic control. Apidra could be administered subcutaneously using syringes or specific pens, including the Apidra SoloSTAR disposable pen and the ClikSTAR reusable pen. Apidra is available in approximately 100 countries worldwide. Insuman: Insuman (human insulin) is a range of insulin solutions and suspensions for injection and is indicated for diabetes patients where treatment with insulin is required. Insuman is supplied in vials, cartridges, pre filled disposable pens (OptiSet and SoloSTAR), or reusable pens (ClickSTAR). The Insuman range includes rapid acting insulin solutions (Insuman Rapid and Insuman Infusat) that contain soluble insulin, an intermediate acting insulin suspension (Insuman Basal) that contains isophane insulin, and combinations of fast acting and intermediate acting insulins in various proportions (Insuman Comb). Insuman is principally sold in Germany and emerging markets. Lyxumia: Lyxumia (lixisenatide) is a once daily prandial glucagon-like peptide-1 receptor agonist and is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycemic control. In 2013, the European Commission granted marketing authorization in Europe for Lyxumia. The company initiated a phased launch of Lyxumia in various European Union countries. Lyxumia has been approved in approximately 50 countries and launched in approximately 20 countries around the world. Additional Phase IIIb studies are ongoing. BGStar/iBGStar/MyStar Extra: The company and its partner, AgaMatrix, are co-developing intelligent solutions in diabetes care that demonstrate their commitment to simplifying and innovating the diabetes management experience for people with diabetes and healthcare providers. These blood glucose monitoring solutions are exclusive to the company and are designed to be synergistic with the rest of its diabetes treatment portfolio. MyStar Extra provides parameters, which are critical for insulin titration, such as three day fasting blood glucose average, fasting blood glucose trend over the last 10 days, and estimation of the A1C trend. MyStar Extra is available in various European countries, including Italy, Spain, France, Germany, and the United Kingdom. BGStar and iBGStar are available in various European countries (including France, Germany, Spain, Italy, and the United Kingdom), in Canada, and in some other countries, including Brazil. Rare Diseases The company’s Rare Diseases business is focused on products for the treatment of rare genetic diseases and other chronic debilitating diseases, including lysosomal storage disorders (LSDs), a group of metabolic disorders caused by enzyme deficiencies. Cerezyme: Cerezyme (imiglucerase for injection) is an enzyme replacement therapy used to treat Gaucher disease, an inherited, potentially life threatening LSD. Cerezyme reduces, relieves, and reverses majority of the symptoms and risks of Type 1 and Type 3 (in certain markets) Gaucher disease. Cerezyme is administered by intravenous infusion approximately 1 or 2 hours. The principal markets for Cerezyme are the United States, Europe, and Latin America. Cerdelga: Cerdelga (eliglustat) is the first-line oral therapy for Gaucher disease type 1. A potent, highly specific ceramide analogue inhibitor of GL-1 synthesis with tissue distribution, Cerdelga has demonstrated efficacy in patients who switch from enzyme replacement therapy, as well as in untreated patients. The principal market for Cerdelga is the United States. It received European Medicines Agency (EMA) approval in January 2015. Myozyme/Lumizyme: Myozyme/Lumizyme (alglucosidase alpha) are enzyme replacement therapies used to treat Pompe disease, an inherited, progressive and often fatal LSD. Myozyme is marketed the United States and the European Union, and is av

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHPP:FP €453.42 EUR 0.00

RHPP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $160.44 USD +1.43
Bayer AG €136.80 EUR +1.59
Bristol-Myers Squibb Co $68.40 USD +0.90
GlaxoSmithKline PLC 1,445 GBp +15.00
Medtronic PLC $77.32 USD +0.75
View Industry Companies
 

Industry Analysis

RHPP

Industry Average

Valuation RHPP Industry Range
Price/Earnings 28.2x
Price/Sales 3.4x
Price/Book 2.1x
Price/Cash Flow 17.8x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-TITR PART10%87, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.